Amphastar CFO Says Baqsimi Pricing Won't Fully Recover Even After Record $58.8 Million Quarter
The CFO says the duplicate-discount fix is nearly maxed out, and this year's 3% price increase does not close the gap.
Amphastar Pharmaceuticals, which makes generic and proprietary injectable, inhalation and intranasal medicines, will not get Baqsimi pricing back to earlier levels, CFO Bill Peters said on the company's third-quarter earnings call Thursday. Baqsimi still posted record net sales of $58.8 million, up about 10%.
A ceiling on the 340B fix
Baqsimi is the company's nasal glucagon. Peters said Amphastar has not reached its 80% target for resolving duplicate 340B discounts, the drug-pricing program under which some sales are discounted twice. He does not expect to go past it, "because that's where the other companies that are using the same resources have gotten to."
Pricing was still a drag of about $2.2 million this quarter, which Peters called "a lot better" than in each of the last two quarters. Asked by an analyst whether 2027 pricing could recover, he answered, "we don't think we'll get back to the pricing that we had previously." The 3% price increase taken this year "doesn't fully offset" the problem, he said.
Comparisons should get easier, Peters said, because the peak of the double discounting came in the first quarter of last year. Management expects strong Baqsimi growth in 2027 but is not ready to give guidance.
Record sales, thinner margin
Senior Vice President of Corporate Communications Dan Dischner said Baqsimi's growth came from higher unit volumes, partly offset by lower net pricing tied to commercial discounts and customer mix. Total revenue rose 8% to $207.6 million, the highest the company has recorded in one quarter, from $191.8 million a year earlier.
Gross margin slipped to 48% from 51%. Peters blamed lower prices on Baqsimi, glucagon and the epinephrine multi-dose vial, plus higher costs at the IMS plant, which is under remediation after an FDA warning letter. IMS work added roughly $2 million to $3 million of expense in the quarter, and Peters said it should run a little higher in each of the next two or three quarters.
Net income rose to $37.8 million, or 87 cents a share, from $17.4 million, or 37 cents, a year earlier. The board authorized another $50 million for share buybacks.
IMS backlog and the fourth quarter
Peters said the 10-Q shows a larger backorder at the IMS facility than in the past, now up to $12.5 million, creating competing demands on resources. Lidocaine demand, lifted by another supplier's shortage, should continue into next year, he said.
For the fourth quarter, the company expects sales to rise in the high single digits from a year earlier, a forecast that includes a modest slowdown in IMS sales.
Management said it expects to update investors on progress next quarter.
Sources
- Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates — Yahoo Finance
- Amphastar Pharmaceuticals (NASDAQ:AMPH) reports bullish Q3 2026, stock soars — Yahoo Finance
- Amphastar Pharmaceuticals Inc (AMPH) Q3 2026 Earnings Call Highlights: Record Revenue of $207. ... — Yahoo Finance
- Amphastar: Q3 Earnings Snapshot — Associated Press
- Amphastar: Q3 Earnings Snapshot – WTOP News — wtop.com